Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Evidence for a third sodium-binding site in glutamate transporters suggests an ion/substrate coupling model.

Larsson HP, Wang X, Lev B, Baconguis I, Caplan DA, Vyleta NP, Koch HP, Diez-Sampedro A, Noskov SY.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13912-7. doi: 10.1073/pnas.1006289107. Epub 2010 Jul 15.

2.

Strong cooperativity between subunits in voltage-gated proton channels.

Gonzalez C, Koch HP, Drum BM, Larsson HP.

Nat Struct Mol Biol. 2010 Jan;17(1):51-6. doi: 10.1038/nsmb.1739. Epub 2009 Dec 20.

3.

An acid-activated nucleobase transporter from Leishmania major.

Ortiz D, Sanchez MA, Koch HP, Larsson HP, Landfear SM.

J Biol Chem. 2009 Jun 12;284(24):16164-9. doi: 10.1074/jbc.M109.006718. Epub 2009 Apr 14.

4.

Multimeric nature of voltage-gated proton channels.

Koch HP, Kurokawa T, Okochi Y, Sasaki M, Okamura Y, Larsson HP.

Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9111-6. doi: 10.1073/pnas.0801553105. Epub 2008 Jun 26.

5.
7.

The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3.

Esslinger CS, Agarwal S, Gerdes J, Wilson PA, Davis ES, Awes AN, O'Brien E, Mavencamp T, Koch HP, Poulsen DJ, Rhoderick JF, Chamberlin AR, Kavanaugh MP, Bridges RJ.

Neuropharmacology. 2005 Nov;49(6):850-61. Epub 2005 Sep 23.

PMID:
16183084
8.
9.
10.

Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.

Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G; Prevention of Atrial Fibrillation after Cardioversion Investigators.

Eur Heart J. 2004 Aug;25(16):1385-94.

PMID:
15302102
11.

Fluorometric measurements of conformational changes in glutamate transporters.

Larsson HP, Tzingounis AV, Koch HP, Kavanaugh MP.

Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3951-6. Epub 2004 Mar 4. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12777.

12.

Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters.

Koch HP, Kavanaugh MP, Esslinger CS, Zerangue N, Humphrey JM, Amara SG, Chamberlin AR, Bridges RJ.

Mol Pharmacol. 1999 Dec;56(6):1095-104.

PMID:
10570036
13.

[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].

Fetsch T, Burschel G, Breithardt G, Engberding R, Koch HP, Lukl J, Trappe HJ, Treese N.

Z Kardiol. 1999 Mar;88(3):195-207. German.

PMID:
10355070
15.

Nontransportable inhibitors attenuate reversal of glutamate uptake in synaptosomes following a metabolic insult.

Koch HP, Chamberlin AR, Bridges RJ.

Mol Pharmacol. 1999 Jun;55(6):1044-8.

PMID:
10347246
16.

Structural determinants of substrates and inhibitors: probing glutamate transporters with 2,4-methanopyrrolidine-2,4-dicarboxylate.

Esslinger CS, Koch HP, Kavanaugh MP, Philips DP, Chamberlin AR, Thompson CM, Bridges RJ.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3101-6.

PMID:
9873684
17.

Design and synthesis of conformationally constrained inhibitors of high-affinity, sodium-dependent glutamate transporters.

Chamberlin AR, Koch HP, Bridges RJ.

Methods Enzymol. 1998;296:175-89. No abstract available.

PMID:
9779448
18.

[The long path toward "odorless garlic"].

Koch HP.

Pharm Unserer Zeit. 1996 Jul;25(4):186-91. Review. German. No abstract available.

PMID:
8927631
19.

L-trans-2,3-pyrrolidine dicarboxylate: characterization of a novel excitotoxin.

Willis CL, Humphrey JM, Koch HP, Hart JA, Blakely T, Ralston L, Baker CA, Shim S, Kadri M, Chamberlin AR, Bridges RJ.

Neuropharmacology. 1996 May;35(5):531-9.

PMID:
8887961
20.

[The activity of drugs with homeopathic potency in the "yeast test"].

Koch HP, Partilla A.

Pharmazie. 1995 Jan;50(1):73. German. No abstract available.

PMID:
7886131
21.

[Acute toxicity of pyrrolizidine alkaloids in the "yeast test"].

Koch HP, Plobner K, Trojan M.

Pharmazie. 1994 Dec;49(12):934-5. German. No abstract available.

PMID:
7838885
22.

[The onion--an unjustly ignored medicinal plant].

Koch HP.

Pharm Unserer Zeit. 1994 Dec;23(6):333-9. Review. German. No abstract available.

PMID:
7838859
23.

Pharmacokinetics and organ distribution of liposome-encapsulated L-carnitine in rats.

Jäger W, Koch HP.

Arzneimittelforschung. 1993 Sep;43(9):974-7.

PMID:
8240461
24.

The concept of fractals in the pharmaceutical sciences.

Koch HP.

Pharmazie. 1993 Sep;48(9):643-59. Review.

PMID:
8234397
25.

[Cytotoxic activity of new cyclic lactones in the "yeast test"].

Jäger W, Hofeneder M, Urban E, Koch HP.

Pharmazie. 1993 Jul;48(7):553-4. German. No abstract available.

PMID:
8415853
26.

The yeast test: an alternative method for the testing of acute toxicity of drug substances and environmental chemicals.

Koch HP, Hofeneder M, Bohne B.

Methods Find Exp Clin Pharmacol. 1993 Apr;15(3):141-52.

PMID:
8332030
27.

[Acute toxicity in the "yeast test" of thalidomide, taglutimide and supidimide].

Hofeneder M, Krebs G, Sutter B, Koch HP.

Pharmazie. 1993 Feb;48(2):147-8. German. No abstract available.

PMID:
8475162
28.

[The anti-ischemic effect of gallopamil-retard in comparison with nifedipine-retard in stable angina pectoris].

Rettig GF, Jakob M, Koch HP.

Z Kardiol. 1992 Oct;81(10):525-30. German.

PMID:
1441691
30.
31.

In vitro inhibition of adenosine deaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics.

Koch HP, Jäger W, Groh U, Plank G.

Methods Find Exp Clin Pharmacol. 1992 Jul-Aug;14(6):413-7.

PMID:
1469950
32.

Efficacy and tolerability of slow-release gallopamil in patients with stable exercise-inducible angina pectoris.

Kottkamp H, Gülker H, Emmerich K, Koch HP, Minge C.

J Cardiovasc Pharmacol. 1992;20 Suppl 7:S88-94.

PMID:
1284163
33.

Fractals also in pharmacokinetics?

Koch HP, Zacek H.

Pharmazie. 1991 Dec;46(12):870-1.

PMID:
1818324
34.

Effect of gallopamil on myocardial ischaemia during percutaneous transluminal coronary angioplasty.

Rauch B, Neumann J, Richardt G, Kranzhöfer R, Barth R, Zimmermann R, Koch HP, Tillmanns H, Schömig A.

Drugs. 1991;42 Suppl 1:31-6.

PMID:
1718692
35.

Pharmacokinetics and bioavailability of beta-sitosterol in the beagle dog.

Ritschel WA, Kastner U, Hussain AS, Koch HP.

Arzneimittelforschung. 1990 Apr;40(4):463-8.

PMID:
2357248
36.

Comments on "Proposed Mechanisms of Action in Thalidomide Embryopathy".

Koch HP.

Teratology. 1990 Feb;41(2):243-6. No abstract available.

PMID:
2321169
37.

[Serum theophylline concentrations in patients with chronic obstructive lung diseases: a comparison of 2 methods].

Voshaar T, Schweisfurth H, Schöttes C, Prinsen J, Koch HP.

Pneumologie. 1990 Feb;44 Suppl 1:283-4. German.

PMID:
2195516
38.

Percutaneous absorption of rosmarinic acid in the rat.

Ritschel WA, Starzacher A, Sabouni A, Hussain AS, Koch HP.

Methods Find Exp Clin Pharmacol. 1989 May;11(5):345-52.

PMID:
2755281
39.

[Improvement in solubility and stability of thalidomide by synthesis of inclusion complexes with cyclodextrins].

Koch HP, Steinacker C.

Arch Pharm (Weinheim). 1988 Jun;321(6):371-3. German. No abstract available.

PMID:
3178438
40.

[Drug liberation from floating capsules in the rotating-flask solubility tester].

Koch HP, Mertz M, Zinterhof G.

Pharmazie. 1987 May;42(5):312-5. German.

PMID:
3671440
41.

[In vitro studies of drug liberation from suppositories with the rotating flask method].

Koch HP, Klissenbauer C, Ritzinger A, Wallentin A.

Pharmazie. 1987 Mar;42(3):169-72. German.

PMID:
3602072
43.
44.

Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity?

Koch HP, Czejka MJ.

Z Naturforsch C J Biosci. 1986 Nov-Dec;41(11-12):1057-61.

PMID:
2953123
45.

Silymarin: potent inhibitor of cyclic AMP phosphodiesterase.

Koch HP, Bachner J, Löffler E.

Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13.

PMID:
3001454
46.

Influence of silymarin and some flavonoids on lipid peroxidation in human platelets.

Koch HP, Löffler E.

Methods Find Exp Clin Pharmacol. 1985 Jan;7(1):13-8.

PMID:
3990442
47.

Thalidomide and congeners as anti-inflammatory agents.

Koch HP.

Prog Med Chem. 1985;22:165-242. Review. No abstract available.

PMID:
3915365
48.

In vivo-in vitro correlations with sustained-release theophylline preparations.

Ritschel WA, Koch HP, Alcorn GJ.

Methods Find Exp Clin Pharmacol. 1984 Oct;6(10):609-18.

PMID:
6513678
49.

Cimetidine-sucralfate drug interaction.

Ritschel WA, Banerjee PS, Koch HP, Czeijka M.

Methods Find Exp Clin Pharmacol. 1984 May;6(5):261-3.

PMID:
6547990

Supplemental Content

Support Center